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FoundationSurgery is the only deﬁnitive therapy for severe mitral
regurgitation (MR), and the guidelines recommend that
severe MR in symptomatic or asymptomatic patients with
left ventricular (LV) dysfunction should be managed with
surgery (1,2). However, it remains unclear when asymp-
tomatic patients with severe MR should undergo surgical
intervention because randomized clinical trials comparingAsan Medical Center, College of Medicine,
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013; revised manuscript received February 12,early surgery with watchful waiting have not been performed
(3,4). The beneﬁt of early surgery has been suggested in
prospective, observational studies (5–8), whereas a watchful
waiting strategy seemed to be safe and effective in another
prospective study (9). The consensus guidelines for per-
forming early surgery in asymptomatic patients with severeSee page 2408MR are different, reﬂecting controversy. The current
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) guidelines recommend early surgery
for asymptomatic patients if the success rate of mitral
valve (MV) repair is expected to exceed 90%, but the 2012
European Society of Cardiology guidelines recommend
watchful waiting for such patients (1,2).
The clinical outcomes of asymptomatic patients with
MR are poorly deﬁned (3), and it is important to identify
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2399high-risk patients in whom early surgery may be warranted.
Older patients and those with a larger effective regurgitant
oriﬁce area (EROA) showed increased mortality with
medical management (6,10), but it is controversial whether
early surgery would improve clinical outcome of such pa-
tients because the performance of surgery in high-risk pa-
tients may be associated with increased operative risk.
We previously compared clinical outcomes of early surgery
with those of conventional treatment in asymptomatic severe
MR. In our previous single-center study, early surgery was
signiﬁcantly associated with a reduction in cardiac events,
but no signiﬁcant differences in all-cause or cardiac mortality
were found in a propensity analysis (8). In the present study,
we sought to examine the hypothesis that early surgery
is associated with a signiﬁcant decrease in all-cause and
cardiac mortalities using a propensity analysis of greater
registry data collected prospectively at 2 centers and to
conﬁrm whether early surgery would be more beneﬁcial to
older patients with a larger EROA.Methods
Study population. A prospective registry, started in 1996
at Asan Medical Center and in 2001 at Samsung Medical
Center, has included all consecutive patients with MR un-
dergoing echocardiography at our hospitals. Case report
forms, including patient demographics, clinical presentation,
and echocardiographic data, were stored in an electronic
database (8). Comorbidity was assessed using the Charlson
comorbidity scale, which assigns weights to speciﬁc co-
morbid disease states (11). Clinical and echocardiographic
follow-up data of study patients were collected annually
and entered into the database. From 1996 to 2009, 1,505
patients had a diagnosis of severe degenerative MR at
the time of enrollment, but 93 patients who had an
EROA <0.4 cm2 were not included in the analysis. Of the
1,412 patients who had an EROA 0.4 cm2 and received a
diagnosis of severe degenerative MR, 601 patients with
exertional dyspnea were excluded; 811 patients were assessed
for eligibility, 16 of whom were not candidates for surgery
and 185 of whom were excluded according to the recom-
mendations of the 2006 ACC/AHA guidelines for surgical
indications of asymptomatic severe MR (1). Because the
presence of coronary artery disease is an important prog-
nostic factor, and concomitant coronary artery bypass graft
operation may increase the operative risk, patients with a
history of coronary artery disease or regional wall motion
abnormalities were also excluded, but 25 patients with
incidental coronary artery disease detected on pre-operative
coronary angiography were not excluded. Of the 786 patients
requiring surgery and excluded from the study, 649 (83%)
underwent surgery with 9 (1.4%) operative mortalities. MV
repair and replacement were performed in 503 (78%) and
146 (22%) patients, respectively (Online Table 1). Baseline
clinical and echocardiographic characteristics of excluded
patients are listed in Online Table 2. The primary cohortcomprised 610 asymptomatic
patients (364 men, 50  14 years
of age) with chronic severe
degenerative MR who were po-
tential candidates for early surgery
(Fig. 1). The treatment groups
were not assigned randomly.
Instead, the choice of early sur-
gery or conventional treatment for
each patient was at the discretion
of the attending physician, who
explained the potential beneﬁts
and procedural risks of early sur-
gery in detail and, most impor-
tantly, took the preferences of the
individual patients into account.
Early elective surgery was per-
formed on 235 patients (early
surgery group) within 6 months of the initial echocardio-
graphic evaluation, and the conventional treatment strategy
was chosen for 375 patients (conventional treatment group).
Because in the absence of hypertension, there is no known
indication for the use of medical therapy in asymptomatic
patients with MR and preserved LV systolic function, pa-
tients in the conventional treatment group were observed
without medical therapy and were referred for surgery if ex-
ertional dyspnea developed and they had an LV ejection
fraction (EF) 0.60, LV end-systolic dimension 40 mm,
Doppler estimated pulmonary artery pressure >50 mm Hg,
or atrial ﬁbrillation. Informed consent was obtained from each
patient, and the study protocol was separately approved by the
ethics committees of our institutions.
Echocardiographic evaluation. Echocardiographic evalu-
ation was performed at baseline and annually during
follow-up. Two-dimensional echocardiography and Doppler
color ﬂow imaging were performed on all patients using
a Hewlett-Packard Sonos 2500, 5500, or 7500 imaging
system (Hewlett-Packard, Andover, Massachusetts) and
a VIVID 7 or E9 ultrasound system (General Electric
Healthcare, Little Chalfont, United Kingdom). End-
diastolic dimension and end-systolic dimension of the left
ventricle were measured from parasternal M-mode acquisi-
tions, and the end-systolic volume, end-diastolic volume,
and EF of the left ventricle were calculated with the biplane
Simpson method (12). Comprehensive echocardiographic
evaluation of MR was performed using the integrated
approach of 2-dimensional, Doppler, and color ﬂow imag-
ing. With the simpliﬁed proximal isovelocity surface area
(PISA) method, the degree of MR was graded as mild
(PISA radius <4 mm), moderate (PISA radius <8 mm),
and severe (PISA radius 8 mm) (13). Severe degenerative
MR was deﬁned as severe prolapse and/or ﬂail leaﬂet of
the MV with an EROA of holosystolic MR 0.4 cm2.
The EROA was determined by dividing the regurgitant
ﬂow rate, calculated as 2pr2  aliasing velocity, where r is
the PISA radius, by peak MR velocity (14). In the patients
Figure 1 Flow Diagram of Study Patients
EF ¼ ejection fraction; EROA ¼ effective regurgitant oriﬁce area; ESD ¼ end-systolic dimension; HT ¼ hypertension; MR ¼ mitral regurgitation.
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2400with eccentric or multiple MR jets for which PISA is
less accurate, the EROA was also obtained by volumetric
methods based on quantitative Doppler measurement of
mitral and aortic stroke volumes (15,16). Regurgitant vol-
ume was also measured in 244 patients (40%) with an
acceptable envelope of MR jet. Transesophageal echocar-
diography was performed in 452 patients (74%) to evaluate
the functional anatomy of the MV in detail and to assess the
feasibility of repair.
Surgical procedures. The procedures were performed
with the use of standard cardiopulmonary bypass. In the
early surgery group, MV repair and replacement were per-
formed successfully in 222 (94%) and 13 (6%) patients,
respectively, and concomitant coronary artery bypass grafting
at the time of MV surgery was performed on 23 patients
(10%), with bypass grafts of 2.1  1.2 vessels. MV repair
was performed with the following techniques singly or in
combination: new chord formation, quadrangular resection,
and commissuroplasty, and all but 2 patients also underwentannuloplasty with an annular ring, the mean size of which
was 30.2  2.2 mm.
Follow-up. All the study patients were asked to visit
their attending physician regularly every 6 to 12 months,
and the study coordinators called them if they missed
their appointment for annual follow-up. Data were obtained
during annual visits to the outpatient clinic or echocardio-
graphic laboratory until March 2013. Operative mortality
was deﬁned as death within 30 days of surgery. Deaths were
classiﬁed as cardiac or noncardiac on the basis of the medical
records. Regular follow-up was complete for 514 patients
(84%), and follow-up information was complemented by
telephone interviews in 96 patients (16%) with irregular
follow-up. Follow-up information was complete for 598
patients (98%). For the 8 patients (2%) in the conventional
treatment group, and the 4 patients (2%) in the early surgery
group who were lost to follow-up, data on the vital status,
dates, and causes of death were obtained from the Korean
National Registry of Vital Statistics.
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2401The primary endpoint of the study was deﬁned as cardiac
death during follow-up, and the secondary endpoint was
all-cause death and the composite of operative mortality,
cardiac death, repeat MV surgery, and hospitalization due
to congestive heart failure (CHF) during follow-up. A
hospitalization for CHF was deﬁned as an unplanned, ur-
gent admission for the management of CHF. A patient
admitted for CHF had to show resting dyspnea and radio-
logical signs of pulmonary edema and require intravenous
diuretics.
Statistical analysis. Categorical variables are presented as
numbers and percentages and were compared using the chi-
square test and Fisher exact test. Continuous variables are
expressed as mean  SD and were compared using the
Student unpaired t test or the Mann-Whitney U test.
Analysis of the clinical endpoint was performed on an
intention-to-treat basis. Event-free survival curves were
constructed with Kaplan-Meier estimates and compared by
using the log-rank test. For Kaplan-Meier analysis, we
analyzed all clinical events by time to ﬁrst event and theTable 1 Baseline Characteristics of Patients Who Underwent Early S
Overall Cohor
Early Surgery Group
(n ¼ 235)
Conventional Treatment
Group
(n ¼ 375)
Age, yrs 50.5  14.0 50.2  14.6
Male 130 (55) 234 (62)
Body surface area, m2 1.70  0.19 1.72  0.18
Body mass index, kg/m2 24.0  3.4 23.9  3.3
Smoking 85 (36) 98 (26)
Diabetes 13 (6) 21 (6)
Chronic renal insufﬁciency 1 (0.4) 2 (0.5)
Hypertension 87 (37) 138 (37)
Drug therapy
ACE inhibitor 19 (8) 19 (5)
Angiotensin receptor blocker 37 (16) 44 (12)
Calcium antagonist 21 (9) 30 (8)
Beta-blocker 16 (7) 22 (6)
Diuretics 34 (14) 32 (9)
Cholesterol, mg/dl 176  48 177  49
Additive EuroSCORE 1.10  1.21 1.04  1.31
Charlson comorbidity index 0.59  0.90 0.54  1.12
Reasons for echocardiography
Cardiac murmur alone 60 (26) 125 (33)
Referral from other hospitals 167 (71) 237 (63)
Pre-operative consultation* 8 (3) 13 (4)
End-systolic dimension, mm 34.9  4.1 34.4  3.8
End-diastolic dimension, mm 58.8  5.5 57.2  5.1
Left atrial dimension, mm 47.0  6.8 45.6  6.5
Ejection fraction, % 66.0  5.2 65.6  4.6
Prolapsed segment
Anterior 45 (19) 65 (17)
Posterior 128 (54) 213 (57)
Both 62 (26) 97 (26)
EROA, cm2 0.86  0.37 0.76  0.33
Values are mean  SD or n (%). *Pre-operative consultation for noncardiac surgery.
ACE ¼ angiotensin-converting enzyme; EROA ¼ effective regurgitant oriﬁce area; EuroSCORE ¼ Europpatients in the conventional treatment group who developed
criteria for MV surgery but refused to undergo surgery
were censored at the time an indication for surgery devel-
oped. Cox proportional hazards analysis was performed to
compare hazard rates of outcomes between the early surgery
and conventional treatment groups.
To reduce the effect of treatment selection bias and po-
tential confounding in this observational study, we per-
formed rigorous adjustment for the differences in baseline
characteristics using propensity-score matching (17). The
propensity scores were estimated without regard to outcome
variables, using multiple logistic regression analysis. All
prespeciﬁed covariates were included in the full non-
parsimonious models for treatment with early surgery versus
conventional strategy (Table 1). The discrimination and
calibration ability of the propensity-score model was assessed
by means of the C statistic (C ¼ 0.691) and the Hosmer-
Lemeshow statistic (chi-square ¼ 6.165, df ¼ 8, p ¼
0.63). The propensity score–matched pairs were created by
matching early surgery and conventional strategy subjects onurgery and Those Who Underwent Conventional Treatment
t Propensity Score–Matched Cohort
p Value
Early Surgery Group
(n ¼ 207)
Conventional Treatment
Group
(n ¼ 207) p Value
0.82 50.5  14.2 49.0  14.1 0.28
0.08 116 (56) 115 (56) 0.92
0.21 1.71  0.19 1.72  0.19 0.54
0.67 24.1  3.3 23.9  3.4 0.53
0.008 69 (33) 63 (30) 0.53
0.97 11 (5) 10 (5) 0.82
1.00 1 (0.5) 1 (0.5) 1.00
0.96 75 (36) 78 (38) 0.76
0.13 15 (7) 11 (5) 0.41
0.16 34 (16) 24 (12) 0.16
0.68 17 (8) 13 (6) 0.45
0.64 14 (7) 8 (4) 0.19
0.02 30 (14) 20 (10) 0.13
0.83 177  47 175  49 0.73
0.26 1.09  1.21 1.02  1.21 0.39
0.012 0.58  0.87 0.54  1.11 0.29
0.12 0.66
55 (27) 51 (25)
147 (71) 148 (71)
5 (2) 8 (4)
0.15 34.7  4.1 34.7  3.8 0.97
<0.001 58.3  5.6 58.3  5.1 0.96
0.013 46.4  6.7 46.4  6.4 0.96
0.38 65.8  5.0 65.6  4.7 0.64
0.81 0.83
40 (19) 45 (22)
116 (56) 113 (55)
51 (25) 49 (24)
0.001 0.82  0.34 0.81  0.37 0.94
ean System for Cardiac Operative Risk Evaluation score; MR ¼ mitral regurgitation.
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2402the logit of the propensity score using calipers of width equal
to 0.2 of the SD of the logit of the propensity score (18). A
Greedy matching was performed by using the %GMATCH
macro; the Division of Biostatistics at the Mayo Clinic
provides a set of SAS macros on its website (19) for
propensity-score matching. After propensity-score matching,
the baseline covariates were compared between the 2 groups
with a paired t test or Wilcoxon signed rank test for
continuous variables and the McNemar test or marginal
homogeneity test for categorical variables (Table 1). We also
examined the similarity of early surgery and conventional
treatment strategy subjects in the propensity score–matched
sample by calculating standardized differences for each of
the baseline variables listed in Table 1. All of the stan-
dardized differences for each of the baseline variables
were <0.10 (10%) after matching. In the propensity score–
matched cohort, the risks of clinical endpoints were
compared using Cox regression models with robust standard
errors that accounted for the clustering of matched pairs.
Moreover, we also adjusted for differences in baseline
characteristics in the overall cohort by using weighted Cox
proportional hazards regression models with inverse prob-
ability of treatment weighting method (20), with weights
for patients receiving early surgery being the inverse of
(1  propensity score) and weights for patients receiving
conventional treatment being the inverse of propensity score.
All reported p values were 2 sided, and a value of p < 0.05
was considered statistically signiﬁcant. SAS software, version
9.1 (SAS Institute, Inc., Cary, North Carolina), was used
for statistical analyses.Results
Baseline characteristics. The baseline clinical and echo-
cardiographic characteristics of the early surgery and con-
ventional treatment group were compared, as shown in
Table 1. There were no signiﬁcant differences between theFigure 2 Comparison of Endpoints in the Overall Cohort
Kaplan-Meier curves for the cumulative probabilities of overall mortality (A), cardiac mort
CONV ¼ conventional treatment group; OP ¼ early surgery group.2 groups in terms of age, sex, body mass index, diabetes
mellitus, hypertension, EF, EuroSCORE (European Sys-
tem for Cardiac Operative Risk Evaluation score), and
location of prolapsed segments. However, the early surgery
group had a signiﬁcantly higher Charlson comorbidity index
and a signiﬁcantly larger EROA, LV dimensions, and left
atrial diameter (p < 0.05). Regurgitant volume was also
signiﬁcantly larger in the early surgery group than in the
conventional treatment group (96  31 ml vs. 84  31 ml,
p < 0.01). Propensity-score matching for the overall cohort
yielded 207 matched pairs of patients, the ages of whom
ranged from 16 to 82 years. In the matched cohort, there
were no longer any signiﬁcant differences between the
early surgery group and the conventional treatment group
for any covariates, according to the use of statistical methods
appropriate for matched data (Table 1).
Comparison of outcomes in the overall cohort. There
were no cases of operative mortality in the early surgery
group. The median follow-up was 7.5 years (interquartile
range, 5.4 to 10.9 years) in the early surgery group and
8.2 years (interquartile range, 5.5 to 10.9 years) in the
conventional treatment group (p ¼ 0.50). The patients in
the conventional treatment group in whom an indication for
surgery developed, but who were not operated on, were
censored at the time that they reached criteria for surgery,
and 1 sudden death, 5 CHF deaths, and 1 noncardiac death
that occurred after censoring were not counted in the end-
points. During follow-up, there were 1 cardiac and 14
noncardiac deaths in the early surgery group and 13 cardiac
and 18 noncardiac deaths in the conventional treatment
group. The estimated actuarial 12-year mortality rates were
9  3% in the early surgery group and 12  2% in the
conventional treatment group (p ¼ 0.46) ) (Fig. 2A). The
causes of noncardiac deaths were malignancy (n ¼ 6),
stroke (n ¼ 5), infection (n ¼ 1), suicide (n¼ 1), and trauma
(n ¼ 1) in the early surgery group, and malignancy (n ¼ 12),
stroke (n ¼ 2), infection (n ¼ 1), trauma (n ¼ 2), andality (B), and cardiac event (C) according to treatment group in the overall cohort.
Table 2 HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment
No. of Events Unadjusted Adjusted by IPTW
Early Surgery
(n ¼ 272)
CONV
(n ¼ 417) HR (95% CI) p Value HR (95% CI) p Value
All-cause death 15 31 0.791 (0.427–1.465) 0.46 0.613 (0.320–1.177) 0.14
Cardiac death 1 13 0.124 (0.016–0.944) 0.044 0.136 (0.018–1.028) 0.053
Cardiac event 6 40 0.240 (0.102–0.566) 0.001 0.205 (0.085–0.492) < 0.001
CI ¼ conﬁdence interval; CONV ¼ conventional treatment; HR ¼ hazard ratio; IPTW ¼ inverse probability of treatment weights.
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2403dementia (n ¼ 1) in the conventional treatment group.
The causes of cardiac deaths in the conventional treatment
group were sudden cardiac death in 8 patients, CHF in 1,
operative mortality after late urgent surgery in 1, endo-
carditis in 2, and acute myocardial infarction in 1, whereas
1 cardiac death in the early surgery group was due to CHF
related to a recurrence of severe MR. The mean ages of
14 patients who died of cardiac causes later were 65  9
years at the time of enrollment. The risk of cardiac mortality
was signiﬁcantly lower in the early surgery group (HR:
0.124; 95% CI: 0.016 to 0.944; p ¼ 0.044), and the esti-
mated actuarial 12-year cardiac mortality rates were 1  1%
in the early surgery group and 5  2% in the conventional
treatment group (p ¼ 0.016) (Fig. 2B). Four patients in the
early surgery group and 1 patient in the conventional
treatment group underwent repeat MV surgery, and 1 pa-
tient in the early surgery group and 26 patients in the
conventional treatment group required hospitalization for
CHF without cardiac mortality. Thus, 6 patients (2.6%) in
the early surgery group and 40 patients (10.7%) in the
conventional treatment group attained the composite
endpoint, and the estimated actuarial 12-year event rate was
5  2% in the early surgery group and 18  3% in the
conventional treatment group (p < 0.001) (Fig. 2C). The
risk of a cardiac event was signiﬁcantly lower in the early
surgery group than in the conventional treatment group on
unadjusted and adjusted Cox proportional hazard model
analysis by the inverse probability of treatment weighting
method (Table 2).
Although occurrences of atrial ﬁbrillation and stroke were
not pre-speciﬁed endpoints, persistent or post-operativeTable 3 Comparison of Echocardiographic Results Between the Earl
Early Surgery Group (n ¼ 235)
Baseline Post-Operative
End-systolic dimension, mm 34.9  4.1* 33.8  4.8y 3
End-diastolic dimension, mm 58.8  5.5 49.5  5.0y 4
End-systolic volume, ml 48.4  18.4 40.8  17.1y 3
End-diastolic volume, ml 139.2  44.3 93.3  31.9y 9
Ejection fraction, % 66.0  5.2 56.8  8.0 6
Recurrence of MR
Moderate MR d d
Severe MR d d
Values are mean  SD or n (%). *p < 0.05. yp < 0.01 versus late surgery group.
MR ¼ mitral regurgitation.paroxysmal atrial ﬁbrillation occurred in 50 patients (21.2%)
in the early surgery group and in 35 patients (9.3%) in the
conventional treatment group during follow-up, nonfatal
and fatal strokes occurred in 6 patients (2.6%) in the early
surgery group, and in 7 patients (1.9%) in the conventional
treatment group during follow-up.
In the conventional treatment group, 99 patients (26%)
underwent late MV surgery with MV repair (n ¼ 81) or
MV replacement (n ¼ 18) at the mean interval of 4.4 
3.1 years after enrollment. There was 1 operative mortality
(1.0%) in the conventional treatment group with late sur-
gery, and the repair rate was signiﬁcantly lower than that in
the early surgery group (82% vs. 94%, p < 0.001). The
operative mortality and repair rate in the conventional
treatment group with late surgery were similar to those of
patients excluded due to the presence of symptoms or
echocardiographic criteria for surgery. The early surgery
group and the conventional treatment group with late sur-
gery were compared in terms of the results of echocardio-
graphic examinations performed after surgery and during
follow-up (Table 3). The 2 treatment groups were similar
in terms of LV dimensions, volumes, and EF at baseline,
but the early surgery group had signiﬁcantly smaller LV
dimensions and volumes on immediate post-operative
echocardiographic examinations. In the early surgery group,
12 patients (5.1%) had recurrences of moderate (n ¼ 9) or
severe (n ¼ 3) MR, and 4 (1.5%) underwent repeat MV
surgeries due to severe symptomatic MR (n ¼ 2), infective
endocarditis (n ¼1), or severe symptomatic mitral stenosis
due to pannus formation at the annular ring (n ¼ 1). The
estimated actuarial 12-year rates of MR recurrence andy Surgery and Late Surgery Groups
Late Surgery Group (n ¼ 99)
Follow-Up Baseline Post-Operative Follow-Up
0.4  4.3y 35.8  3.0 36.4  5.4 32.3  5.0
8.2  4.6 59.4  4.4 51.8  6.0 49.3  5.4
7.9  13.8 48.1  15.2 49.6  20.5 40.6  13.8
4.6  29.0 141.3  38.9 109.7  33.2 101.1  29.7
1.3  5.6 66.2  4.7 55.4  8.0 60.1  5.8
9 (3.8) d d 1 (1.0)
3 (1.3) d d 1 (1.0)
Table 4 HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment in the Propensity Score-Matched Cohort
No. of Events Propensity Score Matching
Early Surgery
(n ¼ 207)
CONV
(n ¼ 207) HR (95% CI) p Value
All-cause death 11 22 0.509 (0.241–1.077) 0.078
Cardiac death 1 9 0.109 (0.014–0.836) 0.033
Cardiac event 5 23 0.216 (0.083–0.558) 0.002
Abbreviations as in Table 2.
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2404repeat MV surgery in the early surgery group were 8  2%
and 3  2%, respectively.
Comparison of outcomes in the propensity score–
matched cohort. For the 207 propensity–score matched
pairs, the early surgery group had a signiﬁcantly lower
cardiac mortality rate (1  1% vs. 6  2% at 12 years,
p ¼ 0.010) and cardiac event rate (4  2% vs. 19  4% at
12 years, p ¼ 0.001) (Fig. 3). Cox regression model with
robust SEs also revealed that the early surgery group had
signiﬁcantly lower risks of cardiac death (HR: 0.109; 95%
CI: 0.014 to 0.836; p ¼ 0.033) and cardiac events (HR:
0.216; 95% CI: 0.083 to 0.558; p ¼ 0.002) than the con-
ventional treatment group (Table 4).
Subgroup analysis according to age. Subgroup analysis
was performed to determine the impact of early surgery
on cardiac endpoint according to age. In the 283 patients
younger than 50 years of age, there were 1 cardiac and
3 noncardiac deaths, and in the 327 patients 50 years of age
and older, there were 13 cardiac and 29 noncardiac deaths.
On Cox proportional hazard model analysis, the early sur-
gery group had a signiﬁcantly lower risk of cardiac mortality
than the conventional treatment group in the patients
50 years of age and older, but the difference was not sig-
niﬁcant in terms of overall mortality (Table 5). In patients
50 years of age and older, the risk of a cardiac event was
signiﬁcantly lower in the early surgery group than in the
conventional treatment group (p ¼ 0.002), but not signiﬁ-
cantly different in those aged younger than 50 years of ageFigure 3 Comparison of Endpoints in a Propensity Score–Matched C
Kaplan-Meier curves for the cumulative probabilities of overall mortality (A), cardiac mort
score–matched cohort.(p ¼ 0.20). In the propensity score–matched analysis of
those 50 years of age and older, the early surgery group also
had a signiﬁcantly lower risk of cardiac mortality (HR:
0.120; 95% CI; 0.015 to 0.932; p ¼ 0.043) and cardiac
events (HR: 0.189; 95% CI; 0.066 to 0.543; p ¼ 0.002) than
the conventional treatment group. In patients 50 years of age
and older, the early surgery group had a signiﬁcantly lower
cardiac mortality rate (2  2% vs. 9  3%, p ¼ 0.017)
and cardiac event rate (6  3% vs. 26  5%, p ¼ 0.001) at
12 years (Fig. 4).Discussion
Principal ﬁndings. In this propensity analysis of a large
cohort of asymptomatic patients with severe MR and pre-
served LV systolic function, early surgery was associated
with signiﬁcant long-term reductions of cardiac mortality
and cardiac events. We previously reported that early surgery
was associated with an improved cardiac event rate at 7 years
for the 127 propensity score–matched pairs, but signiﬁcant
reductions in cardiac mortality could not be demonstra-
ted due to the small number of patients and insufﬁcient
follow-up duration (8). Merging prospective registry data
of 2 centers and lengthening follow-up duration to 12
years provided our study with sufﬁcient power to compare
cardiac mortalities between the 2 management strategies in a
propensity analysis. The larger number of study patients also
made it possible to show that the risk-to-beneﬁt ratios ofohort
ality (B), and cardiac event (C) according to treatment group in a propensity
Table 5 HRs for Clinical Outcomes of Early Surgery Compared With Conventional Treatment According to Age
No. of Events Unadjusted
Early Surgery CONV HR (95% CI) p Value
Age <50 yrs n ¼ 106 n ¼ 177
All-cause death 2 2 1.76 (0.25–12.51) 0.57
Cardiac death 0 1 NC
Cardiac event 1 7 0.26 (0.03–2.08) 0.20
Age 50 yrs n ¼ 129 n ¼ 198
All-cause death 13 29 0.67 (0.35–1.30) 0.24
Cardiac death 1 12 0.125 (0.016–0.960) 0.046
Cardiac event 5 33 0.221 (0.086–0.567) 0.002
NC ¼ not calculable; other abbreviations as in Table 2.
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subgroups. Moreover, our previous study could not show
a signiﬁcant difference in repair rate between the early sur-
gery group and the conventional treatment group with late
surgery (8), but this study demonstrates that the repair rate
of late surgery was signiﬁcantly lower than early surgery.
Durability of early MV repair. Before early pre-emptive
surgery can be recommended, it must be associated with
very low operative mortality (<1%), high repair rates, and
high durability of repair (21). The long-term beneﬁt of early
surgery has been questioned by previous reports suggesting
increased risks of reoperation and recurrence of MR (22,23).
The operative mortalities in asymptomatic patients who had
MV repair ranged from 0% to 0.5% in experienced centers
(24,25), and a recent study of early surgery (26) yielded
long-term overall mortality rate of 14  4% at 10 years,
which is similar to that in the present study. Repair rates
and durability of MV repair in large mitral repair centers are
similar to those observed in the present study, reporting
repair rates >90% with low reoperation rates <5% at
10 years (27–29). In addition to the very low operative
mortality and high repair rate found in our previous study,
the present study conﬁrms the durability of early MV repairFigure 4 Comparison of Endpoints in Patients 50 Years of Age and O
Kaplan-Meier curves for the cumulative probabilities of overall mortality (A), cardiac mort
of age and older. Abbreviations as in Figure 1.by showing very low long-term rates of reoperation and
recurrence of MR.
Clinical implications. Early surgery was associated with a
signiﬁcant decrease in cardiac mortality and cardiac event for
patients 50 years or age and older, but there were no sig-
niﬁcant differences between the early surgery and the con-
ventional treatment groups in those younger than 50 years of
age. A recent study that enrolled older patients (mean age,
65  13 years) with ﬂail mitral leaﬂets also reported that
early surgery was associated with greater long-term survival
and a lower risk of heart failure (30). Because aging is
related to progression of MR and poor tolerance to MR
(31), clinical outcomes were different in relation to the age
of patients included in previous observational studies (6,9).
The natural history of asymptomatic MR (10) also showed
that 10-year cardiovascular morbidity was signiﬁcantly
higher for patients 50 years of age and older than for those
younger than 50 years of age at diagnosis (45  4% vs.
10  2%). Considering that patients aged younger than
50 years of age have excellent outcomes and a conventional
treatment strategy may decrease the number of surgeries
performed, it is possible that a watchful waiting strategy may
play a role in the initial management of such patients.lder
ality (B), and cardiac event (C) according to treatment group in patients 50 years
Kang et al. JACC Vol. 63, No. 22, 2014
Early Surgery for Asymptomatic Severe Mitral Regurgitation June 10, 2014:2398–407
2406Furthermore, the clinical practice of valve repair is globally
insufﬁcient, and only 69% of patients undergo MV repair
according to data from the Society of Thoracic Surgeons
database (32). However, it should be noted that in these low-
risk patients, early and late surgeries may differ signiﬁcantly
in terms of repair rates and post-operative LV dysfunction;
moreover, compared with early surgery, conventional treat-
ment of low-risk patients requires more frequent clinical and
echocardiographic follow-up examinations and prompt
referral to surgery once they reach surgical criteria (33). The
current ACC/AHA guidelines suggest a medical manage-
ment approach in elderly patients because operative mortality
increases and survival is reduced in patients older than
75 years of age (1). Because the patients included in the
propensity analysis ranged to 82 years, our results may not
be applicable to elderly patients older than 75 years of age.
Quantitative assessment of MR is strongly recommended
in the guidelines, and measurement of the EROA has an
important prognostic value (34). In a large prospective study
of MR, Enriquez-Sarano et al. (6) reported that patients
with an EROA 0.4 cm2 had excess mortality and that a
greater survival beneﬁt was associated with surgery for larger
EROAs and suggested that patients with an EROA 0.4
cm2 should promptly be considered for cardiac surgery.
However, proponents of the watchful waiting argued that
this study did not provide a basis for early surgery because
early surgery was not compared directly with the watchful
waiting strategy (23). Although randomized trials are
required to establish indications for early surgery, ethical and
ﬁnancial constraints prevent us from conducting a ran-
domized trial. Given the absence of randomized trials, a
recent study by Suri et al. (30) and our study support the
early surgery strategy by demonstrating signiﬁcant differ-
ences in the rate of primary endpoints between groups in
both risk-adjusted models and propensity score–matched
cohorts and strongly suggest that early surgery should be
considered for patients who are older than 50 years of age
and have an EROA 0.4 cm2 or ﬂail mitral leaﬂets.
Study limitations. Comparison of treatment strategies was
subject to the limitations inherent to nonrandomized
assignment, and such limitations may have signiﬁcantly
affected our results due to selection bias and unmeasured
confounders. To control for the inherent biases related to
treatment selection and heterogeneity in baseline factors,
we performed a propensity analysis, which consistently
showed signiﬁcantly lower rates of cardiac endpoints in the
early surgery group. Although it would be desirable that
prospective, randomized clinical trials conﬁrm the efﬁcacy
of early surgery, in the absence of such studies, the results
of the present study provide the strongest observational
evidence that early surgery is effective for asymptomatic
patients with severe MR.
Because the operative mortality was very low in the
present study, our results may not be applicable to patients
at high operative risk. Current guidelines recommend that
asymptomatic patients with severe MR should be seen every6 months (1,2) and annual follow-up was not enough for
close monitoring of high-risk patients. Regular follow-up
was partially complete, and not every patient in the con-
ventional treatment group complied with a watchful waiting
strategy during the entire follow-up. Although a differential
impact of angiotensin-converting enzyme inhibitors,
angiotensin receptor blockers, and beta-blockers might have
altered relative hazards between the 2 groups, it could not be
analyzed. The large sample size of our study provided suf-
ﬁcient number of patients for a propensity analysis, but
it was not possible in the subgroup analysis to analyze the
heterogeneity of treatment effects on tests for interaction due
to the small number of endpoints observed in the early
surgery group. It might be considered a limitation that an
analysis was not performed of this entire registry and was
retrospectively limited to patients with an EROA 0.4 cm2.
Conclusions
Compared with conservative management, early surgery
is associated with an improved long-term outcome by
decreasing cardiac mortality and cardiac events in asymp-
tomatic patients with severe MR in a propensity analysis.
Although early surgery is generally the preferred strategy
for asymptomatic patients with severe MR, the difference
in cardiac event rates was not signiﬁcant among patients
aged younger than 50 years of age.
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